Biogen (BIIB) Operating Income (2009 - 2026)
Biogen (BIIB) posted quarterly Operating Income of -$644.5 million for Q2 2026, down 563.67% year-over-year from $139.0 million in Q2 2025, and down 127.5% quarter-over-quarter from -$283.3 million in Q1 2026.
Biogen (BIIB) Operating Income (2009 - 2026) Analysis & Trends
Biogen's Operating Income history runs 18 years deep, the most recent figure standing at -$644.5 million for Q2 2026.
- In Q2 2026, Operating Income fell 563.67% year-over-year to -$644.5 million; the TTM figure through Jun 2026 stood at -$1.6 billion (down 142.32% YoY), while the FY2025 annual figure was -$847.7 million, down 109.62% from the prior year.
- Operating Income for Q2 2026 stood at -$644.5 million, down from -$283.3 million in the prior quarter.
- The five-year high for Operating Income was $901.6 million in Q3 2022, with the low at -$800.8 million in Q3 2023.
- The 5-year median for Operating Income is -$97.2 million (2024), against an average of -$12.5 million.
- The sharpest annual moves came in 2024 and 2026: Operating Income soared 76.56% in 2024, then tumbled 563.67% in 2026.
- Biogen's Operating Income stood at $439.8 million in 2022, then plunged by 70.99% to $127.6 million in 2023, then slumped by 328.84% to -$292.0 million in 2024, then slumped by 88.87% to -$551.5 million in 2025, then dropped by 16.86% to -$644.5 million in 2026.
- Business Quant data shows BIIB's Operating Income at -$644.5 million in Q2 2026, -$283.3 million in Q1 2026, and -$551.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 7.14 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 6.43 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -584.00 Mn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 4.75 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 3.16 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 3.51 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -10.39 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 4.27 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 645.35 Mn |
| 10 | Biogen | 32.04 Bn | 30.76 Bn | 1.96 Bn | -644.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -644.50 Mn |
| Mar 31, 2026 | -283.30 Mn |
| Dec 31, 2025 | -551.50 Mn |
| Sep 30, 2025 | -117.10 Mn |
| Jun 30, 2025 | 139.00 Mn |
| Mar 31, 2025 | -318.10 Mn |
| Dec 31, 2024 | -292.00 Mn |
| Sep 30, 2024 | -187.70 Mn |
| Jun 30, 2024 | 152.70 Mn |
| Mar 31, 2024 | -77.40 Mn |
| Dec 31, 2023 | 127.60 Mn |
| Sep 30, 2023 | -800.80 Mn |
| Jun 30, 2023 | 115.40 Mn |
| Mar 31, 2023 | -224.50 Mn |
| Dec 31, 2022 | 439.80 Mn |
| Sep 30, 2022 | 901.60 Mn |
| Jun 30, 2022 | 785.50 Mn |
| Mar 31, 2022 | 610.70 Mn |
| Dec 31, 2021 | 587.10 Mn |
| Sep 30, 2021 | 794.00 Mn |